Express Scripts looks to force Gilead to cut price of Sovaldi

|About: Express Scripts, Inc. (ESRX)|By:, SA News Editor

Express Scripts (ESRX) plans to ask its clients, which include employers, health insurance plans and government agencies, to join a group that would stop using Gilead's (GILD) Sovaldi treatment for Hepatitis C once the FDA has approved rival drugs.

Express Scripts has already said it could block reimbursement for Sovaldi once other therapies are on the market, which could come next year.

Gilead has come under intense criticism for charging $84,000 for a 12-week course of Sovaldi.

Express Scripts' annual Drug Trend Report estimates that spending on specialty drugs such as Sovaldi increased 14% in 2013 and forecasts it will jump a further 63% by the end of 2016.